Diabetes in relation to Barrett’s esophagus and adenocarcinomas of the esophagus: a pooled study from the International Barrett’s and Esophageal Adenocarcinoma Consortium

Jessica Petrick* (Corresponding Author), Nan Li, Lesley Anderson, Leslie Bernstein, Douglas A Corley, Hashem B El-Serag, Sheetal Hardikar, Linda Liao, Geoffrey Liu, Liam Murray, Joel H Rubenstein, Jennifer I. Schneider, Nicholas J Shaheen, Aaron P. Thrift, Piet van den Rubenstein, Thomas L Vaughan, David C Whiteman, Anna H Wu, Wei Zhao, Marilie D GammonMichael B Cook

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Background:Diabetes is positively associated with various cancers, but its relationship with tumors of the esophagus/esophagogastric junction remains unclear.Methods:Data were harmonized across 13 studies in the International Barrett's and Esophageal Adenocarcinoma Consortium, comprising 2309 esophageal adenocarcinoma (EA) cases, 1938 esophagogastric junction adenocarcinoma (EGJA) cases, 1728 Barrett's esophagus (BE) cases, and 16,354 controls. Logistic regression was used to estimate study‐specific odds ratios (ORs) and 95% CIs for self‐reported diabetes in association with EA, EGJA, and BE. Adjusted ORs were then combined using random‐effects meta‐analysis.Results:Diabetes was associated with a 34% increased risk of EA (OR, 1.34; 95% CI, 1.00‐1.80; I2 = 48.8% [where 0% indicates no heterogeneity, and larger values indicate increasing heterogeneity between studies]), 27% for EGJA (OR, 1.27; 95% CI, 1.05‐1.55; I2 = 0.0%), and 30% for EA/EGJA combined (OR, 1.30; 95% CI, 1.06‐1.58; I2 = 34.9%). Regurgitation symptoms modified the diabetes‐EA/EGJA association (P for interaction = .04) with a 63% increased risk among participants with regurgitation (OR, 1.63; 95% CI, 1.19‐2.22), but not among those without regurgitation (OR, 1.03; 95% CI, 0.74‐1.43). No consistent association was found between diabetes and BE.Conclusions:Diabetes was associated with increased EA and EGJA risk, which was confined to individuals with regurgitation symptoms. Lack of an association between diabetes and BE suggests that diabetes may influence progression of BE to cancer.
Original languageEnglish
Pages (from-to)4210-4223
Number of pages14
Issue number23
Early online date6 Sept 2019
Publication statusPublished - 1 Dec 2019

Bibliographical note

Funding Information
National Cancer Institute
National Institutes of Health. Grant Numbers: K23DK079291, R01CA001833, R01CA116845, K23DK059311, R01DK063616, K08DK002697, R01CA059636, R01CA030022, R37CA041530, U01CA057949, R01CA109193, U01CA199336, U54CA163059
Research & Development Office (Belfast, Northern Ireland)
Health Research Board (Dublin, Ireland)
Ulster Cancer Foundation
The Netherlands Cancer Foundation and the Dutch Digestive Disease Foundation
Queensland Cancer Fund
National Health and Medical Research Council
Kaiser Permanente Community Benefit Grant
California Tobacco Related Research Program. Grant Number: 3RT‐0122
US Department of Veteran's Affairs Clinical Science Research and Development. Grant Number: I01‐CX000899


  • Barrett esophagus
  • diabetes
  • epidemiology
  • esophageal adenocarcinoma
  • meta-analysis


Dive into the research topics of 'Diabetes in relation to Barrett’s esophagus and adenocarcinomas of the esophagus: a pooled study from the International Barrett’s and Esophageal Adenocarcinoma Consortium'. Together they form a unique fingerprint.

Cite this